Please login to the form below

Not currently logged in
Email:
Password:

Cardioxyl appoints Novartis scientist as chief medical officer

Shi Yin Foo joins cardiovascular specialist

Cardioxyl Shi Yin Foo Cardioxyl Pharmaceuticals has appointed Novartis' Dr Shi Yin Foo as chief medical officer.

Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at US-based cardiovascular specialist Cardioxyl.

This experience includes time as a clinical and translational medicine reviewer for numerous studies from phase I to phase III clinical trials.

“Her unique combination of both early- and late-stage cardiovascular development experience combined with her extensive clinical experience in the treatment of patients with heart failure will serve as an excellent complement to Cardioxyl's proprietary expertise in the biology, physiology and chemistry of nitroxyl donors," said Dr Chris Kroeger, Cardioxyl's president and CEO.

Dr Foo spent four years at Novartis from 2009 have joined the pharma company from her role as a physician at Massachusetts General Hospital in the US, where she specialised in cardiology.

16th September 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...
BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....

Infographics